COVID-19 may be putting the brakes on a broad swath of biopharma deals, but it has also triggered a host of partnerships for coronavirus countermeasures, pushing vaccine deals to their highest numbers in years. Many...

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...

Stephen Hansen, Associate Editor Europe's Iceberg 2015 Despite world-class research institutions and a crop of novel drugs making their way through the clinic, European biotech is finding it hard to reach the end zone with...

The U.K. government is responding to calls for a dementia therapy by 2025 by securing nearly £120 million ($205 million) from U.K.-based organizations for a series of research initiatives that span R&D from discovery to...

Europe's Innovative Medicines Initiative launched the GETREAL (see BioCentury, Dec. 23, 2013) . BC Staff...

Europe's Innovative Medicines Initiative launched the European Gram-Negative Antibacterial Engine (ENABLE) project to progress antibacterial research programs through discovery and Phase I testing. The goal is to move at least one novel antibacterial for Gram-negative...

Consortia led by the Critical Path Institute and Europe's Innovative Medicines Initiative (IMI) partnered to develop new biomarkers to predict, diagnose and monitor drug-induced injury to the liver, kidney and vascular system. The Predictive Safety...

SciBX 's second annual comprehensive analysis of public-private partnerships and early stage venture financing activity reveals that government institutions and organizations are taking a significant role in forming and funding partnerships, and California-based companies are...

Europe's Innovative Medicines Initiative has launched seven new public-private partnerships with a total budget of €237 million ($313 million). In contrast to many of the organization's disease-focused projects, three of the new consortia are taking...

Europe's Innovative Medicines Initiative is expanding its NewDrugs4BadBugs (ND4BB) initiative, which was launched in May to support the development of new antibiotics. The details came in IMI's eighth call for proposals to fund public-private partnerships...